belantamab mafodotin,pembrolizumab
merck,gsk
['pembro', 'multiple myeloma', 'belantamab mafodotin']
our dr. attaya suvannasankha ( ) and her colleagues shared their expertise on safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma. #asco22 #researchcurescancer 
Indiana University Melvin and Bren Simon Comprehensive Cancer Center | The state's only NCI-designated comprehensive cancer center | A leader in cancer research